Translocation T(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report

Overview

Journal Balkan J Med Genet

Publisher Sciendo

Specialty Genetics

Date 2015 Mar 6

PMID 25741217

Authors

S Mesanovic

H Sahovic

M Peric

Affiliations

Soon will be listed here.

Abstract

The myeloproliferative diseases (MPDs) or myelo-proliferative neoplasms (MPNs) are a group of diseases of the bone marrow in which excess cells are produced. Chronic idiopathic myelofibrosis (CIMF) is a stem cell defect characterized by splenomegaly with multiorgan extramedullary hematopoiesis, immature peripheral blood granulocytes and erythrocytes and progressive bone marrow fibrosis. The most common chromosomal abnormalities seen in CIMF patients include numerical changes of chromosomes 7, 8 and 9, and structural changes of 1q, 5q, 13q and 20q. At least 75.0% of patients with bone marrow abnormalities have one or more of these chromosomal anomalies. Detection of the Janus kinase 2 (JAK2) mutation may be a potential major breakthrough for understanding the pathobiology of MPNs, and is an essential part of the diagnostic algorithm. In this study, we describe a JAK2(V617F) mutation negative CIMF patient who has the chromosomal translocation t(3;12)(q26;q21) in her karyotype.

References

Jones A, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L . Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6):2162-8. DOI: 10.1182/blood-2005-03-1320. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

Reilly J, Snowden J, Spearing R, Fitzgerald P, Jones N, Watmore A . Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997; 98(1):96-102. DOI: 10.1046/j.1365-2141.1997.1722990.x. View

Dupriez B, Morel P, Demory J, Lai J, Simon M, Plantier I . Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996; 88(3):1013-8. View

Andrieux J, Demory J, Morel P, Plantier I, Dupriez B, Caulier M . Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet Cytogenet. 2002; 137(1):68-71. DOI: 10.1016/s0165-4608(02)00554-x. View

Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N . EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer. 2005; 45(4):349-56. DOI: 10.1002/gcc.20295. View

Ahmed A, Chang C . Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis. Arch Pathol Lab Med. 2006; 130(8):1133-43. DOI: 10.5858/2006-130-1133-CIM. View

Nunoda K, Sashida G, Ohyashiki K, Kodama A, Fukutake K . The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: impact of the 12q21 breakpoint. Cancer Genet Cytogenet. 2005; 164(1):90-1. DOI: 10.1016/j.cancergencyto.2005.06.014. View

Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

10.

Przepiorka D, Bryant E, Kidd P . Idiopathic myelofibrosis in blast transformation with 4;12 and 5;12 translocations and a 7q deletion. Cancer Genet Cytogenet. 1988; 30(1):139-44. DOI: 10.1016/0165-4608(88)90102-1. View

11.

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

12.

Kvasnicka H, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R . Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997; 80(4):708-19. DOI: 10.1002/(sici)1097-0142(19970815)80:4<708::aid-cncr9>3.0.co;2-i. View

13.

Steensma D, Dewald G, Lasho T, Powell H, McClure R, Levine R . The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005; 106(4):1207-9. PMC: 1895198. DOI: 10.1182/blood-2005-03-1183. View